Prevalence of H. Pylori in Stomach Cancers in the West Indies (PyloCaGe)

Centre Hospitalier Universitaire de la Guadeloupe

Status: Enrolling

Conditions: Oncology Epidemiology; Risk Factors

Study type: Observational

Funder types: Other

Identifiers

NCT07233447

PAP_RIPH2_2020/27

Details and patient eligibility

About

The incidence and mortality of stomach cancer are higher in the French West Indies than in mainland France. The prevalence of H. pylori infection associated with this cancer remains unknown in these populations. The main objective of the study is to estimate the prevalence of H. Pylori detected by immunohistochemistry in patients newly diagnosed with cancer.

Full description

Stomach cancer is the 4th most common cancer site in the world and the 3rd cause of mortality. It is associated with infection by the Helicobacter Pylori bacterium, which colonizes the gastric mucosa in 80% of cases. The decrease of the prevalence of H. pylori infection in developed countries with the advent of antibiotic treatments is responsible for the decrease in the incidence of stomach cancer. But in the French West Indies, stomach cancer remains in excess incidence and mortality compared to France. The prevalence of H. pylori infection remains unknown, both in general population and in patients with stomach cancer. Eating habits combining high consumption of salt, meat and smoked fish could partly explain these high incidences. Furthermore, recent observations suggest that environmental risk factors (pesticides pollution) could also be involved in the occurrence of this cancer. Estimating the prevalence of H. pylori in stomach cancers will improve the epidemiological knowledge of this cancer with high incidence rates and prevention measures.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient over 18 years of age residing in Guadeloupe for more than 6 months and with a primary diagnosis of gastric cancer
• Patient having read the information note and having signed the consent to participate in the study
• Patient with social security coverage.

Exclusion criteria

• Refusal to participate.
• Patient who could not answer the questionnaires
• Patient not affiliated to a social security scheme
• Patient under legal protection (judicial safeguard, guardianship, curatorship, etc.)
• Pregnant or breastfeeding woman
• Subject participating in another research study that includes an exclusion period still ongoing at the time of pre-inclusion